Altogether, these findings suggest that GPR84 endorses anti-tumor immunity by inducing pro-inflammatory TAMs via the STAT1 pathway and that targeting this pathway can improve the efficacy of ICB. This evidence concerns the gene GPR84 and neoplasm.